<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6310">
  <stage>Registered</stage>
  <submitdate>13/01/2017</submitdate>
  <approvaldate>13/01/2017</approvaldate>
  <nctid>NCT03049189</nctid>
  <trial_identification>
    <studytitle>Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients</studytitle>
    <scientifictitle>A Prospective, Randomised, Controlled, Open-label, Multicentre Phase III Study to Evaluate Efficacy and Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Targeted Molecular Therapy With Everolimus in Patients With Inoperable, Progressive, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumours of Gastroenteric or Pancreatic Origin (GEP-NET)</scientifictitle>
    <utrn />
    <trialacronym>COMPETE</trialacronym>
    <secondaryid>ITM-LET-01</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Neuroendocrine Tumors</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Neuroendocrine tumour (NET)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - 177Lu-edotreotide PRRT
Treatment: drugs - Everolimus
Other interventions - Amino-Acid Solution

Experimental: 177Lu-edotreotide PRRT - 177Lu-edotreotide (177Lu-DOTATOC)
A maximum of four cycles of 7.5 GBq (gigabequerel) 177Lu-edotreotide, each. Route of administration: Slow intravenous infusion/injection (i.v.) Duration of treatment: 4 cycles, 90 days apart (total duration: 270 days/9 months)

Active Comparator: Everolimus - Everolimus (Afinitor Â®)
Doses: 10 mg/d Route of administration: Oral Duration of treatment: Continuous daily treatment until diagnosis of progression or End of Study (EOS)


Treatment: drugs: 177Lu-edotreotide PRRT
PRRT using 177Lu-edotreotide will be performed 3-monthly. A maximum of four cycles will be administered.

Treatment: drugs: Everolimus
Everolimus will be adminstered as a standard dosis of 10 mg daily which may be reduced where required for acceptable tolerability.

Other interventions: Amino-Acid Solution
The Amino-Acid Solution (AAS) to be used in this study will contain a mixture of 25 g lysine and 25 g arginine diluted in 2000 mL of electrolyte solution, infused over 4 - 6 h, starting 30 - 60 min before PRRT

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>progression-free survival (PFS) - PFS will be assessed individually per patient from date of randomization until the date of first documented progression, assessed up to 24 months, primary outcome will be measured by CT/MRI every 12 weeks +/- 14 days</outcome>
      <timepoint>12 weeks +/- 14 days, up to 24 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>overall survival (OS) - OS as secondary outcome measure will be assessed per patient from date of randomization until the date of death, whichever came first</outcome>
      <timepoint>every 3 months for a period of at least 24 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Histologically and clinically confirmed diagnosis of well-differentiated
             neuro-endocrine tumour of non-functional gastroenteric origin (GE-NET) or both
             functional or non-functional pancreatic origin (P-NET)

          -  Measurable disease per RECIST 1.1

          -  Somatostatin receptor positive (SSTR+) disease

          -  Radiological disease progression, defined as progressive disease per RECIST 1.1.
             criteria</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Known hypersensitivity to edotreotide or everolimus

          -  Known hypersensitivity to DOTA, lutetium-177, or any excipient of edotreotide or
             everolimus

          -  Prior exposure to any peptide receptor radionuclide therapy (PRRT)

          -  Prior therapy with mTor inhibitors

          -  Prior EFR (extended field radiation) to GEP-NET lesions or radioembolisation therapy

          -  Therapy with an investigational compound and/or medical device within 30 days prior to
             randomisation

          -  Indication for surgical lesion removal with curative potential

          -  Planned alternative therapy (for the period of study participation)

          -  Serious non-malignant disease

          -  Renal, hepatic, cardiovascular, or haematological organ dysfunction, potentially
             interfering with the safety of the study treatments

          -  Pregnant or breast-feeding.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>2/02/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>300</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/05/2021</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>Royal North Shore Hospital - Saint Leonards</hospital>
    <hospital>Olivia Newton-John Cancer &amp; Wellness Centre, Austin Hospital - Heidelberg</hospital>
    <hospital>Peter MacCallum Cancer Centre - Melbourne</hospital>
    <postcode>2065 - Saint Leonards</postcode>
    <postcode>3084 - Heidelberg</postcode>
    <postcode>3000 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wien</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bron</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Clichy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montpellier</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Berka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bonn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Homburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Marburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Wurzburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Meldola</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gliwice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warsaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Pretoria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Basel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Bern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Liverpool</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>ITM Solucin GmbH</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>ABX CRO</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide
      Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus
      in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+),
      neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03049189</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Konstantin Zhernosekov, Dr</name>
      <address />
      <phone />
      <fax />
      <email>info@itm-solucin.de</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>